Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 230

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 230
---
, develop and manage a portfolio of drug candidates that are safer and more effective than competing products. ____________ 3 https: // www.ke.hku.hk/story/innovation/the -magic-of-chinese-yam-for-treatment-of-menopausal-syndrome ;see also, Scientific Reports, 5 -10179. 4 https://www.everydayhe alth.com / menopause / osteoporosis -and-menopause .aspx 125 Inflation Inflation affects us by generally increasing our cost of labor and research and development costs, the way it does to all labor and research costs. However, we do not anticipate that inflation will materially affect our business in the foreseeable future. Seasonality We believe our operation and sales do not experience seasonality. Employees As of the date hereof, we have we have 2 full -timeemployees, one of whom is the CEO and the other who is engaged in general and administrative functions and who is located in Asia. We have also engaged and may continue to engage 5 independent contracted consultants and advisors to assist us with our operations. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We have never experienced any employment related work stoppages, and we consider our relations with our employees to be good. Intellectual Property The technologies underlying our various research and development projects are the subject of various patents and patent applications claiming, in certain instances, composition of matter and, in other instances, methods of use. Prosecution, maintenance and enforcement of these patents, as well as those on any future protectable technologies we may acquire, are and will continue to be an important part of our strategy to develop and commercialize novel medicines, as described in more detail below. Through entering into license agreements with their owners, we have obtained exclusive rights to these patents, applications and related know -howin the U.S. and certain other countries to develop, manufacture and commercialize the products using or incorporating the protected inventions that are described in this registration statement and that are expected to contribute significant value to our business. The technologies protected by these patents may also for the basis for the development of other products. In addition to licensed intellectual property, our in -housescience team has been actively developing our own proprietary intellectual property. No non -provisionalpatent application has yet been filed in the Company’s own name for the Lead Projects. We have, however, filed a number of provisional applications to establish earlier filing dates for certain of our other ongoing research